CD33 CAR T Therapy: Redefining AML Treatment

Introduction

Acute Myeloid Leukemia (AML) is one of the deadliest forms of leukemia, with over 20,000 new cases annually in the U.S. Despite advancements, existing treatments often fall short, leaving patients with high relapse rates and poor survival outcomes. PromiCell’s CD33 CAR T therapy, built on cutting-edge SAVVY-IL18 technology, is redefining AML treatment, offering hope where little existed before.

Why CD33 is the Ideal Target

CD33 is a cell surface protein expressed in over 80% of AML cases. Its role in leukemia pathogenesis makes it a prime target for immunotherapy.

Key advantages include:

• Specificity: CD33 is predominantly expressed on AML cells, and myeloid cells.
• Comprehensive Targeting: The therapy not only eliminates leukemic cells but also targets progenitor cells, reducing the risk of relapse.

‍

PromiCell’s Innovations in CD33 CAR T Therapy

PromiCell leverages the SAVVY-IL18 platform, which integrates advanced engineering to enhance the therapy’s efficacy and scalability:

1.   IL-18 Armoring:

     •   Boosts immune cell recruitment and persistence.

     •   Remodels the tumor microenvironment, ensuring a robust anti-tumor response.

‍

2.   Superior Potency

• Demonstrated greater efficacy compared to benchmarks like CD33 CAR T therapy

(https://jitc.bmj.com/content/9/9/e003149)

‍

3.   Rapid Turnaround and Scalability:

     •   SAVVY-IL18 enables faster manufacturing, allowing treatments to reach patients more quickly without compromising quality.

‍

Preclinical Success

Preclinical studies for CD33 CAR T therapy have yielded impressive results:  

 •   Up to a 100% disease control rate in aggressive AML preclinical models

 •   Significantly outperforms the current best-in-class clinically utilized CD33 CAR T cell (https://jitc.bmj.com/content/12/5/e009013)

These outcomes demonstrate the therapy’s potential to set a new standard in AML care. 

‍

Future Potential and Market Relevance

AML remains one of the most aggressive leukemias, with the highest mortality rate among all types. PromiCell’s CD33 CAR T therapy addresses a critical gap in treatment options, offering a scalable and effective solution for patients who previously had none. With Phase I trials anticipated to begin by late 2025, the therapy is poised to transform the AML treatment landscape.

PromiCell’s CD33 CAR T therapy is not just an advancement—it’s a revolution in AML care. By combining specificity, potency, and scalability, this therapy offers new hope to patients battling this devastating disease. As PromiCell continues its mission to outsmart cancer, the future of AML treatment looks brighter than ever. Stay updated as we move closer to delivering these life-saving therapies to patients in need.

‍